 Johnson & Johnson (J&J) is a leading global diversified health and pharmaceutical company in many regards. It’s research and development (R&D) programs have received increasing funding from the company. In 2019, J&J expended 11.4 billion U.S. dollars on research and development programs. This is a significant increase from 2010 when the company spent 6.8 billion dollars on R&D. Johnson & Johnson’s global positioning Globally there are several top pharmaceutical companies, however Johnson & Johnson stand out about many of them with research and development being a top priority for the company. Therefore, it is no surprise that J&J is among the top three pharmaceutical companies based on its R&D spending. Johnson & Johnson also has one of the largest current research and development pipelines among global pharmaceutical companies. The importance of pharmaceutical R&D Among all industries, pharmaceuticals and biotechnology are among those with the largest investments in research and development. Pharmaceutical research and development is the process in which pharmaceutical companies apply research to generate new pharmaceutical products which in most cases involves clinical trials. The number of drugs being researched and developed globally has never been higher than in recent years. However, the success rate for new drugs in development is only around 10 percent. 